Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is supported by a durable HIV franchise that continues to outperform, with 3Q26 revenue of $8.3B, HIV sales of $6.25B, and raised FY26 HIV growth guidance of 12%, driven by Biktarvy leadership, strong PrEP uptake, and Yeztugo’s $305M early contribution. The company also has meaningful diversification upside from oncology, where Trodelvy grew 42% y/y and cell therapy could reaccelerate with anito-cel, while emerging inflammation assets and tuck-in acquisitions expand optionality. Strong operating cash flow of $5.0B, $6.4B in cash, and disciplined capital returns help offset the longer-term Biktarvy IRA pricing reset, making the overall growth and cash-generation profile compelling.

Gilead Sciences is facing a negative outlook because its core HIV and HCV franchises are vulnerable to generic HIV entrants, intensified competition, and greater-than-expected pricing pressure, which could erode the cash flow base that has historically supported the business. Its oncology push also carries meaningful execution risk, as slower Yescarta uptake, failure to expand its label, or setbacks in Trodelvy clinical trials could limit the contribution from newer growth assets. In addition, potential cuts in federal HIV spending and broader macro weakness could further pressure results, while downside scenarios already imply materially weaker estimates if these risks compound.